Vivalen®

Lenvatinib

Product Information

  • Proprietary Name: Vivalen®
  • Generic Name: Lenvatinib
  • Dosage Form: Capsule
  • Strengths: 4 mg, 10 mg
  • Indications: Advanced or progressive thyroid cancer, Hepatocellular carcinoma (HCC), Advanced endometrial carcinoma, Advanced renal cell carcinoma (RCC)
Download Leaflet

Oncology

Vivalen®

Lenvatinib is indicated for the treatment of advanced or progressive thyroid cancer, hepatocellular carcinoma (HCC), advanced endometrial carcinoma, advanced renal cell carcinoma (RCC).

© NanoAlvand. All rights reserved. Powered by ِDGN.